摘要
Immunotherapy has achieved great success recently and opened a new avenue for anti-tumor treatment. Programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) are typical immune checkpoints that transmit coinhibitory signals, muting the host immunity. Monoclonal antibodies that block PD-1/PD-L1 axis have benefited many patients with different tumor diseases. However, the objective response rate is still unsatisfactory. In this review, we summarize three strategies targeting PD-L1 based on different forms of PD-L1 and various regulating mechanisms to enhance the therapeutic effect, including blockade of the interaction between PD-L1 and PD-1, downregulation of PD-L1 expression and degradation of mature PD-L1. Thereinto, we describe a variety of materials have been designed to target PD-L1, including antibodies, nanoparticle, peptide, aptamer, RNA, and small molecule. Additionally, we list the drugs with PD-L1 regulation capacity used in clinical and ongoing studies to explore other alternatives for targeting PD-L1 besides anti-PD-L1 monoclonal antibodies. Moreover, we discuss associated opportunities for cancer combination therapy with other modalities such as chemotherapy, radiotherapy, photodynamic therapy (PDT) and photothermal therapy (PTT), as these conventional or emerging modalities are capable of increasing the immune response of tumor cells by altering the tumor microenvironment (TME), and would display synergistic effect. At last, we give a brief summary and outlook regarding the research status and future prospect of immunotherapy.
学科与关键词
- Combining PD-L1 inhibitors with immunogenic cell death triggered by chemo-photothermal therapy via a thermosensitive liposome system to stimulate tumor-specific immunological response (Aug, 10.1039/d1nr03288g, 2021)Yu, Jie; He, Xidong; Wang, Zigui; Wang, Yupeng; Liu, Sha; Xie, Zhigang; Li, Xiaoyuan*; Huang, Yubin*Nanoscale, 2021, 13(32): 13907-13907.
- Designing Peptide-Based Nanoinhibitors of Programmed Cell Death Ligand 1 (PD-L1) for Enhanced Chemo-immunotherapyXie, Fengjuan; Tang, Shasha; Zhang, Ye; Zhao, Yinbing; Lin, Yingying; Yao, Yining; Wang, Meiyan*; Gu, Zhengying*; Wan, Jingjing*ACS Nano, 2024, 18(2): 1690-1701.
- The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancersTang, Qing; Chen, Yun; Li, Xiaojuan; Long, Shunqin; Shi, Yao; Yu, Yaya; Wu, Wanyin*; Han, Ling*; Wang, Sumei*Frontiers in Immunology, 2022, 13: 964442.被引 57
